Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bomedemstat - Imago BioSciences

Drug Profile

Bomedemstat - Imago BioSciences

Alternative Names: Bomedemstat tosylate - Imago BioSciences; IMG-241 bis-tosylate salt; IMG-7289; LSD1 inhibitor - Imago BioSciences; MK-3543

Latest Information Update: 25 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Imago BioSciences
  • Developer Imago BioSciences; University of Hong Kong
  • Class Amides; Amines; Antihaemorrhagics; Antineoplastics; Benzamides; Benzene derivatives; Cyclopropanes; Fluorobenzenes; Piperazines; Small molecules; Triazoles
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis; Essential thrombocythaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Essential thrombocythaemia
  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera
  • Phase I/II Small cell lung cancer

Most Recent Events

  • 12 Apr 2024 University of Washington in a collaboration with Imago BioSciences suspends a phase I/II trial in Small Cell Lung Cancer (Combination therapy) in USA (PO) due to drug supply issue (NCT05191797)
  • 08 Apr 2024 Merck Sharp & Dohme plans a phase III trial for Myelofibrosis and Essential thrombocythaemia (Treatment-experienced) in May 2024 (PO, Capsule) (NCT06351631)
  • 31 Dec 2023 Phase-III clinical trials in Essential thrombocythaemia (Treatment-experienced) in Israel (PO) (NCT06079879)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top